0001104659-22-029462.txt : 20220302 0001104659-22-029462.hdr.sgml : 20220302 20220302190041 ACCESSION NUMBER: 0001104659-22-029462 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220302 DATE AS OF CHANGE: 20220302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harris Matthew Scott CENTRAL INDEX KEY: 0001787762 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 22705831 MAIL ADDRESS: STREET 1: C/O ALTIMMUNE, INC. STREET 2: 910 CLOPPER ROAD, SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 4 1 tm228203-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-02-28 0 0001326190 Altimmune, Inc. ALT 0001787762 Harris Matthew Scott C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S GAITHERSBURG, MD 20878 0 1 0 0 Chief Medical Officer Common Stock, par value $0.0001 2022-02-28 4 M 0 30000 1.9213 A 41545 D Common Stock, par value $0.0001 2022-02-28 4 S 0 30000 7.52 D 11545 D Stock Options (option to buy) 1.9213 2022-02-28 4 M 0 30000 0.00 D 2030-01-02 Common Stock, par value $0.0001 30000 31400 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.70, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Twenty-five percent of the shares underlying the option became vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. /s/ Kent Tapper, as Attorney-in-Fact 2022-03-02